Global drugmakers sign China licensing deals
Major international pharmaceutical companies are increasingly partnering with Chinese biotechs to develop innovative RNA therapies and cancer drugs through multi-billion dollar licensing agreements.
Xurve View
Insights:
Xurve View
Abogen signed a licensing deal worth up to $7.8 billion with Swiss drugmaker Novartis AG on Friday morning to develop an RNA-based therapy. The agreement highlights a broader wave of cross-border partnerships connecting developers in China with multinational pharmaceutical giants. Chinese biotech firms routinely retain domestic commercial rights while licensing overseas assets in exchange for upfront fees, milestones, and royalties.
